Genetesis

Genetesis is a clinical-stage medical technology company that specializes in non-invasive biomagnetic imaging to enhance the diagnosis and triage of cardiovascular diseases, particularly myocardial ischemia and coronary artery disease. Founded in 2013 by Peeyush Shrivastava and his co-founders at Ohio State University, the company has grown to a team of around 30 employees and has raised over $40 million in funding. The flagship product, CardioFlux FAC Magnetocardiograph, measures the heart's magnetic field to quickly detect cardiac issues without radiation exposure. It is integrated with the Faraday Analytical Cloud, which uses machine learning to turn raw data into clinically actionable insights. This technology complements existing diagnostic tools and aims to be a primary rule-out test for myocardial ischemia in acute care settings. Genetesis has received FDA Breakthrough Device designation for CardioFlux and has conducted clinical validation through trials with notable institutions like the Cleveland Clinic. The company targets hospitals, cardiology offices, and emergency departments, providing a rapid and cost-effective alternative to traditional cardiac imaging methods.

• Employees 17
• Founded 2013
• Annual Revenue $2700000
• Total Funding $35400000